Products for Research Use Only

DOTA-Octreotide (TFA)

CAT: 0804-HY-P10273A-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P10273A-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
DOTA-Octreotide TFA is composed of chelator DOTA and Octreotide. DOTA-Octreotide TFA is used for research of cancer through combination with radioactive elements. DOTA-Octreotide TFA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
UNSPSC
12352209
Target
Biochemical Assay Reagents; Radionuclide-Drug Conjugates (RDCs)
Related Pathways
Antibody-drug Conjugate/ADC Related; Others
Applications
Cancer-programmed cell death
Field of Research
Cancer
Purity
99.30
Smiles
O=C([C@@H](NC([C@H](CSSC[C@H](NC([C@](NC([C@@H](NC1=O)CCCCN)=O)([H])[C@H](O)C)=O)C(N[C@H](CO)[C@H](O)C)=O)NC([C@H](NC(CN2CCN(CCN(CCN(CC2)CC(O)=O)CC(O)=O)CC(O)=O)=O)CC3=CC=CC=C3)=O)=O)CC4=CC=CC=C4)N[C@@H]1CC5=CNC6=CC=CC=C56.O=C(O)C(F)(F)F
Molecular Formula
C67H93F3N14O19S2
Molecular Weight
1519.66
References & Citations
[1]Bodei L, et al., Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2004 Jul;31 (7) :1038-46.
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
Scientific Category
Peptides
Clinical Information
No Development Reported
Isoform
RDC Peptide